Skip to content

Study · Non-randomized trial · n = 11 · 2009

14 results

Long-term metabolic and hormonal effects of exenatide on islet transplant recipients with allograft dysfunction.

Faradji RN, Froud T, Messinger S, Monroy K, Pileggi A, Mineo D, Tharavanij T, Mendez AJ, Ricordi C, Alejandro R

Cell transplantation1 Jan 2009Cited by 36 (Europe PMC)

PMID20003758 (opens in a new tab)DOI10.3727/096368909x474456 (opens in a new tab)PepBankPUB-20003758
Source linkPubMedAsk about this study
Jump to 14 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

14 results from studies that gave the peptide. 14 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In islet transplant recipients with graft dysfunction, daily exenatide improved glucose during mixed meal testing.

    In plain wordsIn islet transplant recipients with graft dysfunction, daily exenatide improved blood glucose during meal testing.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Direction not reportedGlucose during chronic treatment
    Study

    n = 11

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Daily exenatide treatment resulted in improved glucose, increased amylin/insulin ratio, and decreased proinsulin/insulin ratio as assessed by MMTT.
    1 context sentence
    Summary · context
    In this prospective, single-arm, nonrandomized study, 11 type 1 diabetes recipients of ITx with GDF had HbA1c, weight, insulin requirements, and 5-h mixed meal tolerance test (MMTT; with/without exenatide given before test) at baseline, 3, 6, and 12 months after initiating exenatide treatment.
  2. 02HumanNon-randomized trialEfficacy outcome

    In islet transplant recipients with graft dysfunction, daily exenatide increased the amylin/insulin ratio.

    In plain wordsIn islet transplant recipients with graft dysfunction, daily exenatide increased the amylin-to-insulin ratio.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseAmylin/insulin ratio
    Study

    n = 11

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Daily exenatide treatment resulted in improved glucose, increased amylin/insulin ratio, and decreased proinsulin/insulin ratio as assessed by MMTT.
    1 context sentence
    Summary · context
    In this prospective, single-arm, nonrandomized study, 11 type 1 diabetes recipients of ITx with GDF had HbA1c, weight, insulin requirements, and 5-h mixed meal tolerance test (MMTT; with/without exenatide given before test) at baseline, 3, 6, and 12 months after initiating exenatide treatment.
  3. 03HumanNon-randomized trialEfficacy outcome

    In islet transplant recipients with graft dysfunction, daily exenatide decreased the proinsulin/insulin ratio.

    In plain wordsIn islet transplant recipients with graft dysfunction, daily exenatide decreased the proinsulin-to-insulin ratio.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseProinsulin/insulin ratio
    Study

    n = 11

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Daily exenatide treatment resulted in improved glucose, increased amylin/insulin ratio, and decreased proinsulin/insulin ratio as assessed by MMTT.
    1 context sentence
    Summary · context
    In this prospective, single-arm, nonrandomized study, 11 type 1 diabetes recipients of ITx with GDF had HbA1c, weight, insulin requirements, and 5-h mixed meal tolerance test (MMTT; with/without exenatide given before test) at baseline, 3, 6, and 12 months after initiating exenatide treatment.
  4. 04HumanNon-randomized trialEfficacy outcome

    In islet transplant recipients with graft dysfunction, glucagon responses remained unchanged during daily exenatide treatment.

    In plain wordsIn islet transplant recipients with graft dysfunction, daily exenatide did not change glucagon responses.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeGlucagon response during chronic treatment
    Study

    n = 11

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Glucagon responses remained unchanged.
    1 context sentence
    Summary · context
    In this prospective, single-arm, nonrandomized study, 11 type 1 diabetes recipients of ITx with GDF had HbA1c, weight, insulin requirements, and 5-h mixed meal tolerance test (MMTT; with/without exenatide given before test) at baseline, 3, 6, and 12 months after initiating exenatide treatment.
  5. 05HumanNon-randomized trialEfficacy outcome

    In islet transplant recipients with graft dysfunction, exenatide before meal testing decreased glucagon at 0 min.

    In plain wordsIn islet transplant recipients with graft dysfunction, exenatide before meal testing lowered premeal glucagon.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreasePremeal glucagon
    Study

    n = 11

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Exenatide administration 1 h before MMTT showed decreased glucagon and glucose at 0 min and attenuation in their postprandial rise.
    1 context sentence
    Summary · context
    In this prospective, single-arm, nonrandomized study, 11 type 1 diabetes recipients of ITx with GDF had HbA1c, weight, insulin requirements, and 5-h mixed meal tolerance test (MMTT; with/without exenatide given before test) at baseline, 3, 6, and 12 months after initiating exenatide treatment.
  6. 06HumanNon-randomized trialEfficacy outcome

    In islet transplant recipients with graft dysfunction, exenatide before meal testing decreased glucose at 0 min.

    In plain wordsIn islet transplant recipients with graft dysfunction, exenatide before meal testing lowered premeal glucose.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreasePremeal glucose
    Study

    n = 11

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Exenatide administration 1 h before MMTT showed decreased glucagon and glucose at 0 min and attenuation in their postprandial rise.
    1 context sentence
    Summary · context
    In this prospective, single-arm, nonrandomized study, 11 type 1 diabetes recipients of ITx with GDF had HbA1c, weight, insulin requirements, and 5-h mixed meal tolerance test (MMTT; with/without exenatide given before test) at baseline, 3, 6, and 12 months after initiating exenatide treatment.
  7. 07HumanNon-randomized trialEfficacy outcome

    In islet transplant recipients with graft dysfunction, exenatide before meal testing attenuated the postprandial glucagon rise.

    In plain wordsIn islet transplant recipients with graft dysfunction, exenatide reduced the glucagon rise after a meal.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreasePostprandial glucagon rise
    Study

    n = 11

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Exenatide administration 1 h before MMTT showed decreased glucagon and glucose at 0 min and attenuation in their postprandial rise.
    1 context sentence
    Summary · context
    In this prospective, single-arm, nonrandomized study, 11 type 1 diabetes recipients of ITx with GDF had HbA1c, weight, insulin requirements, and 5-h mixed meal tolerance test (MMTT; with/without exenatide given before test) at baseline, 3, 6, and 12 months after initiating exenatide treatment.
  8. 08HumanNon-randomized trialEfficacy outcome

    In islet transplant recipients with graft dysfunction, exenatide before meal testing attenuated the postprandial glucose rise.

    In plain wordsIn islet transplant recipients with graft dysfunction, exenatide reduced the glucose rise after a meal.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreasePostprandial glucose rise
    Study

    n = 11

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Exenatide administration 1 h before MMTT showed decreased glucagon and glucose at 0 min and attenuation in their postprandial rise.
    1 context sentence
    Summary · context
    In this prospective, single-arm, nonrandomized study, 11 type 1 diabetes recipients of ITx with GDF had HbA1c, weight, insulin requirements, and 5-h mixed meal tolerance test (MMTT; with/without exenatide given before test) at baseline, 3, 6, and 12 months after initiating exenatide treatment.
  9. 09HumanNon-randomized trialEfficacy outcome

    In islet transplant recipients with graft dysfunction, exenatide delayed peak glucose during meal testing.

    In plain wordsIn islet transplant recipients with graft dysfunction, exenatide delayed peak glucose after a meal.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseTime to peak glucose
    Study

    n = 11

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Time-to-peak glucose was delayed, followed by insulin, proinsulin, amylin, and C-peptide, indicating glucose-driven insulin secretion.
    1 context sentence
    Summary · context
    In this prospective, single-arm, nonrandomized study, 11 type 1 diabetes recipients of ITx with GDF had HbA1c, weight, insulin requirements, and 5-h mixed meal tolerance test (MMTT; with/without exenatide given before test) at baseline, 3, 6, and 12 months after initiating exenatide treatment.
  10. 10HumanNon-randomized trialEfficacy outcome

    In islet transplant recipients completing follow-up, glucose suppression with exenatide was no longer observed after meal testing.

    In plain wordsIn islet transplant recipients completing follow-up, exenatide no longer suppressed glucose after meal testing.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeGlucose suppression at follow-up
    Study

    n = 5

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Glucose and glucagon suppression responses after MMTT with exenatide were no longer observed.
    2 context sentences
    Summary · context
    Five subjects completed 12-month follow-up.
    Summary · context
    In this prospective, single-arm, nonrandomized study, 11 type 1 diabetes recipients of ITx with GDF had HbA1c, weight, insulin requirements, and 5-h mixed meal tolerance test (MMTT; with/without exenatide given before test) at baseline, 3, 6, and 12 months after initiating exenatide treatment.
  11. 11HumanNon-randomized trialEfficacy outcome

    In islet transplant recipients completing follow-up, glucagon suppression with exenatide was no longer observed after meal testing.

    In plain wordsIn islet transplant recipients completing follow-up, exenatide no longer suppressed glucagon after meal testing.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeGlucagon suppression at follow-up
    Study

    n = 5

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Glucose and glucagon suppression responses after MMTT with exenatide were no longer observed.
    2 context sentences
    Summary · context
    Five subjects completed 12-month follow-up.
    Summary · context
    In this prospective, single-arm, nonrandomized study, 11 type 1 diabetes recipients of ITx with GDF had HbA1c, weight, insulin requirements, and 5-h mixed meal tolerance test (MMTT; with/without exenatide given before test) at baseline, 3, 6, and 12 months after initiating exenatide treatment.
  12. 12HumanNon-randomized trialEfficacy outcome

    In transplant follow-up completers, retrospective analysis showed higher sustained glucagon with less profound suppression during exenatide testing.

    In plain wordsIn transplant follow-up completers, earlier testing showed higher glucagon and weaker glucagon suppression with exenatide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    MixedEarly glucagon response in completers
    Study

    n = 5

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    Retrospective 3-month analysis of these subjects revealed higher and sustained glucagon levels that did not suppress as profoundly with exenatide administration, associated with higher glucose levels and increased C-peptide responses.
    2 context sentences
    Summary · context
    Five subjects completed 12-month follow-up.
    Summary · context
    In this prospective, single-arm, nonrandomized study, 11 type 1 diabetes recipients of ITx with GDF had HbA1c, weight, insulin requirements, and 5-h mixed meal tolerance test (MMTT; with/without exenatide given before test) at baseline, 3, 6, and 12 months after initiating exenatide treatment.
  13. 13HumanNon-randomized trialOther

    In transplant follow-up completers, weaker glucagon suppression with exenatide was associated with higher glucose in retrospective analysis.

    In plain wordsIn transplant follow-up completers, weaker glucagon suppression with exenatide was linked to higher glucose in earlier testing.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseEarly glucose in completers
    Study

    n = 5

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    Retrospective 3-month analysis of these subjects revealed higher and sustained glucagon levels that did not suppress as profoundly with exenatide administration, associated with higher glucose levels and increased C-peptide responses.
    2 context sentences
    Summary · context
    Five subjects completed 12-month follow-up.
    Summary · context
    In this prospective, single-arm, nonrandomized study, 11 type 1 diabetes recipients of ITx with GDF had HbA1c, weight, insulin requirements, and 5-h mixed meal tolerance test (MMTT; with/without exenatide given before test) at baseline, 3, 6, and 12 months after initiating exenatide treatment.
  14. 14HumanNon-randomized trialOther

    In transplant follow-up completers, weaker glucagon suppression with exenatide was associated with increased C-peptide responses in retrospective analysis.

    In plain wordsIn transplant follow-up completers, weaker glucagon suppression with exenatide was linked to greater C-peptide responses in earlier testing.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseEarly C-peptide responses in completers
    Study

    n = 5

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    Retrospective 3-month analysis of these subjects revealed higher and sustained glucagon levels that did not suppress as profoundly with exenatide administration, associated with higher glucose levels and increased C-peptide responses.
    2 context sentences
    Summary · context
    Five subjects completed 12-month follow-up.
    Summary · context
    In this prospective, single-arm, nonrandomized study, 11 type 1 diabetes recipients of ITx with GDF had HbA1c, weight, insulin requirements, and 5-h mixed meal tolerance test (MMTT; with/without exenatide given before test) at baseline, 3, 6, and 12 months after initiating exenatide treatment.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.